Astrazeneca (AZN) Long-Term Deferred Tax (2009 - 2026)

Astrazeneca (AZN) has reported Long-Term Deferred Tax for 18 consecutive years, with $5.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Deferred Tax fell 8.24% year-over-year to $5.6 billion; the TTM figure through Mar 2026 stood at $5.6 billion (down 8.24% YoY), while the FY2025 annual figure was $5.8 billion, up 8.83% from the prior year.
• Long-Term Deferred Tax came in at $5.6 billion for Q1 2026 at Astrazeneca, down from $5.8 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $6.3 billion in Q2 2025, with the low at $3.3 billion in Q4 2022.
• Average Long-Term Deferred Tax over 5 years is $4.8 billion, with a median of $4.7 billion recorded in 2023.
• The largest YoY upside for Long-Term Deferred Tax was 51.44% in 2022 against a maximum downside of 24.64% in 2022.
• Year by year, Long-Term Deferred Tax stood at $3.3 billion in 2022, then jumped by 44.59% to $4.7 billion in 2023, then grew by 13.33% to $5.3 billion in 2024, then rose by 8.83% to $5.8 billion in 2025, then dropped by 3.88% to $5.6 billion in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $5.6 billion, $5.8 billion, and $6.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.